ZYUS.V

Healthcare Drug Manufacturers - Specialty & Generic

ZYUS Life Sciences Corporation

CA$0.50

-0.10 -16.67% today

Price History

Not enough data

Key Stats

Market Cap

40.04M

Avg Volume

2,487

EPS

-CA$0.25

52W High

CA$0.75

52W Low

CA$0.37

Div. Yield

0.0%

Valuation

Forward P/E

-1.79

P/B Ratio

-3.01

P/S Ratio

107.05

EV/EBITDA

-7.13

EV/Revenue

192.38

Margins

Gross Margin (15.5%)

Operating Margin (2745.7%)

Net Margin 0.0%

EBITDA Margin 0.0%

Growth & Returns

Revenue Growth (YoY)

(32.5%)

Return on Assets

(87.3%)

Liquidity & Leverage

Current Ratio

0.04

Quick Ratio

0.03

Total Cash

202,000

Total Debt

23.84M

About

ZYUS Life Sciences Corporation manufactures and distributes cannabinoid-based therapeutics and product candidates for medical and adult recreational. The company offers Trichomylin, a softgel capsules with fixed dose combination of cannabinoids formulated that is phase 2a clinical trial for the treatment of chronic pain in adults caused due to musculoskeletal injuries, arthritis, and cancer. It operates in Canada, the United States, Australia, and the European Union. ZYUS Life Sciences Corporation was founded in 2018 and is headquartered in Saskatoon, Canada.